{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:39:23Z","timestamp":1794109163813,"version":"4.8.0"},"reference-count":306,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004853","name":"Chinese University of Hong Kong","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004853","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Retinal and Eye Research"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.preteyeres.2025.101406","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:16:29Z","timestamp":1758773789000},"page":"101406","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["International consensuses and controversies on causes, diagnosis and management of diabetic macular edema (DME)"],"prefix":"10.1016","volume":"109","author":[{"given":"Danny S.C.","family":"Ng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paisan","family":"Ruamviboonsuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajendra S.","family":"Apte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanyam","family":"Bajimaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen K.M.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol Y.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Jen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Voraporn","family":"Chaikitmongkol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Chhablani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taraprasad","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suber S.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jost B.","family":"Jonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy Y.Y.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Chun","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion R.","family":"Munk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Narayanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishant V.","family":"Radke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Sagong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charumathi","family":"Sabanayagam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sobha","family":"Sivaprasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Shimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koh-Hei","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer K.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin S.W.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brijesh","family":"Takkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Virgili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stela","family":"Vujosevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Young","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingfa","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien-Yin","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5276-3702","authenticated-orcid":false,"given":"Dennis S.C.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.preteyeres.2025.101406_bib1","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jcjo.2013.03.004","article-title":"Ranibizumab injection for diabetic macular edema: meta-analysis of systemic safety and systematic review","volume":"48","author":"Abouammoh","year":"2013","journal-title":"Can. J. Ophthalmol."},{"issue":"211","key":"10.1016\/j.preteyeres.2025.101406_bib2","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1016\/j.ophtha.2012.08.002","article-title":"Dexamethasone intravitreal implant during phacoemulsification","volume":"120","author":"Agarwal","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101406_bib3","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/IAE.0b013e3182006da1","article-title":"Phacoemulsification with intravitreal bevacizumab and triamcinolone acetonide injection in diabetic patients with clinically significant macular edema and cataract","volume":"31","author":"Akinci","year":"2011","journal-title":"Retina"},{"key":"10.1016\/j.preteyeres.2025.101406_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41433-020-0961-6","article-title":"Diabetic retinopathy and diabetic macular oedema pathways and management: UK consensus working group","volume":"34","author":"Amoaku","year":"2020","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.preteyeres.2025.101406_bib5","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1167\/iovs.18-25634","article-title":"Deep learning predicts OCT measures of diabetic macular thickening from color fundus photographs","volume":"60","author":"Arcadu","year":"2019","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2025.101406_bib6","first-page":"1819","article-title":"Contrast sensitivity loss is coupled with capillary dropout in patients with diabetes","volume":"38","author":"Arend","year":"1997","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2025.101406_bib7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/jamaophthalmol.2015.4070","article-title":"Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and meta-analysis","volume":"134","author":"Avery","year":"2016","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib8","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1136\/bjophthalmol-2014-305252","article-title":"Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD","volume":"98","author":"Avery","year":"2014","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib9","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1001\/jama.2019.5790","article-title":"Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial","volume":"321","author":"Baker","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.preteyeres.2025.101406_bib10","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1097\/IAE.0000000000000433","article-title":"Vitrectomy with internal limiting membrane peeling for tractional and NONTRACTIONAL diabetic macular edema: long-Term results of a comparative study","volume":"35","author":"Bonnin","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.preteyeres.2025.101406_bib11","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1038\/s41433-024-03364-y","article-title":"Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema","volume":"38","author":"Borchert","year":"2024","journal-title":"Eye"},{"key":"10.1016\/j.preteyeres.2025.101406_bib12","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","article-title":"Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema","volume":"121","author":"Boyer","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101406_bib13","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/archopht.1984.01040031036019","article-title":"Abnormalities of the foveal avascular zone in diabetic retinopathy","volume":"102","author":"Bresnick","year":"1984","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib14","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/eye.2012.53","article-title":"Observational study of subclinical diabetic macular edema","volume":"26","author":"Bressler","year":"2012","journal-title":"Eye (Lond)."},{"key":"10.1016\/j.preteyeres.2025.101406_bib15","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1001\/jamaophthalmol.2015.5346","article-title":"Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment","volume":"134","author":"Bressler","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.preteyeres.2025.101406_bib16","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ajo.2015.12.025","article-title":"Five-year outcomes of ranibizumab with prompt or deferred laser versus laser or triamcinolone plus deferred ranibizumab for diabetic macular edema","volume":"164","author":"Bressler","year":"2016","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib17","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1001\/jamaophthalmol.2017.6565","article-title":"Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial","volume":"136","author":"Bressler","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.preteyeres.2025.101406_bib18","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1097\/IAE.0000000000002302","article-title":"Changes in diabetic retinopathy severity when treating diabetic macular edema with ranibizumab: drcr.net protocol I 5-Year report","volume":"38","author":"Bressler","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.preteyeres.2025.101406_bib19","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1001\/jamaophthalmol.2019.1963","volume":"137","author":"Bressler","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.preteyeres.2025.101406_bib20","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2147\/JHL.S352500","article-title":"An adaptation of the RAND\/UCLA modified Delphi panel method in the time of COVID-19","volume":"14","author":"Broder","year":"2022","journal-title":"J. Healthc. Leader"},{"key":"10.1016\/j.preteyeres.2025.101406_bib21","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.ophtha.2013.02.034","article-title":"Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE","volume":"120","author":"Brown","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101406_bib22","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.ophtha.2015.06.017","article-title":"Intravitreal aflibercept for diabetic macular edema: 100-Week results from the VISTA and VIVID studies","volume":"122","author":"Brown","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101406_bib23","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ajo.2022.01.004","article-title":"KESTREL and KITE: 52-week results from two phase III pivotal trials of brolucizumab for diabetic macular edema","volume":"238","author":"Brown","year":"2022","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib24","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0140-6736(23)02577-1","article-title":"Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-Week results from a randomised, double-masked, non-inferiority, phase 2\/3 trial","volume":"403","author":"Brown","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.preteyeres.2025.101406_bib25","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ophtha.2006.06.052","article-title":"Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema","volume":"114","author":"Browning","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101406_bib26","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s41669-023-00465-4","article-title":"Cost-effectiveness of faricimab in the treatment of diabetic macular oedema (DMO): a UK analysis","volume":"8","author":"B\u00fchrer","year":"2024","journal-title":"Pharmacoecon. Open"},{"key":"10.1016\/j.preteyeres.2025.101406_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1167\/iovs.65.14.1","article-title":"Design and characterization of a novel intravitreal dual-transgene genetic medicine for neovascular retinopathies","volume":"65","author":"Calton","year":"2024","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2025.101406_bib28","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/eye.2016.238","article-title":"Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option","volume":"31","author":"C\u0103lug\u0103ru","year":"2017","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.preteyeres.2025.101406_bib29","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/IAE.0000000000001552","article-title":"Effect of an intravitreal dexamethasone implant on diabetic macular edema after cataract surgery","volume":"38","author":"Calvo","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.preteyeres.2025.101406_bib30","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/546826","article-title":"Inflammatory mediators and angiogenic factors in choroidal neovascularization: pathogenetic interactions and therapeutic implications","volume":"2010","author":"Campa","year":"2010","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.preteyeres.2025.101406_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e4203","article-title":"Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study","volume":"345","author":"Campbell","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.preteyeres.2025.101406_bib32","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.ophtha.2010.12.028","article-title":"Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema","volume":"118","author":"Campochiaro","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101406_bib33","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/j.ophtha.2012.04.030","article-title":"Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema","volume":"119","author":"Campochiaro","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101406_bib34","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ophtha.2019.10.019","article-title":"Treatment patterns for diabetic macular edema: an intelligent research in sight (IRIS\u00ae) registry analysis","volume":"127","author":"Cantrell","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101406_bib35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12886-018-1022-9","article-title":"Intravitreal dexamethasone implant ozurdex\u00ae in na\u00efve and refractory patients with different subtypes of diabetic macular edema","volume":"19","author":"Castro-Navarro","year":"2019","journal-title":"BMC Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib36","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2415-8-5","article-title":"Intravitreal vs. subtenon triamcinolone acetonide for the treatment of diabetic cystoid macular edema","volume":"8","author":"Cellini","year":"2008","journal-title":"BMC Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib37","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1001\/archopht.122.7.1083-b","article-title":"Intravitreal injection of triamcinolone for diffuse diabetic macular edema","volume":"122","author":"Chan","year":"2004","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib38","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1136\/bjo.2006.093211","article-title":"Decreasing efficacy of repeated intravitreal triamcinolone injections in diabetic macular oedema","volume":"90","author":"Chan","year":"2006","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib39","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/IAE.0b013e31823043c6","article-title":"Combined high-dose sub-tenon triamcinolone, intravitreal bevacizumab, and laser photocoagulation for refractory diabetic macular edema: a pilot study","volume":"32","author":"Chan","year":"2012","journal-title":"Retina"},{"key":"10.1016\/j.preteyeres.2025.101406_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1106706","article-title":"Optimizing treatment for diabetic macular edema during cataract surgery","volume":"14","author":"Chan","year":"2023","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib41","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1097\/IAE.0000000000001848","article-title":"Relationship between obstructive sleep apnea and the presence and severity of diabetic retinopathy","volume":"38","author":"Chang","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.preteyeres.2025.101406_bib42","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0140-6736(97)06209-0","article-title":"Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID study group. EURODIAB controlled trial of lisinopril in insulin-dependent diabetes mellitus","volume":"351","author":"Chaturvedi","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.preteyeres.2025.101406_bib43","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/jop.2008.0068","article-title":"The combination of intravitreal bevacizumab and phacoemulsification surgery in patients with cataract and coexisting diabetic macular edema","volume":"25","author":"Chen","year":"2009","journal-title":"J. Ocul. Pharmacol. Therapeut."},{"key":"10.1016\/j.preteyeres.2025.101406_bib44","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1097\/IAE.0000000000001053","article-title":"Subthreshold micropulse diode laser versus conventional laser photocoagulation for diabetic macular edema: a meta-analysis of randomized controlled trials","volume":"36","author":"Chen","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.preteyeres.2025.101406_bib45","article-title":"Factors influencing clinical outcomes in patients with diabetic macular edema treated with intravitreal ranibizumab: comparison between responder and non-responder cases","volume":"9","author":"Chen","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.preteyeres.2025.101406_bib46","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10384-020-00741-4","article-title":"Management of diabetic macular edema: experts' consensus in Taiwan","volume":"64","author":"Chen","year":"2020","journal-title":"Jpn. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib47","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/APO.0000000000000592","article-title":"Latest development on genetics of common retinal diseases","volume":"12","author":"Chen","year":"2023","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"10.1016\/j.preteyeres.2025.101406_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.apjo.2025.100180","article-title":"Updates on medical and surgical managements of diabetic retinopathy and maculopathy","volume":"14","author":"Chen","year":"2025","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"10.1016\/j.preteyeres.2025.101406_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2021.101033","article-title":"Diabetic macular ischaemia \u2013 a new therapeutic target?","volume":"89","author":"Cheung","year":"2022","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.preteyeres.2025.101406_bib50","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1001288","article-title":"Effects of medical therapies on retinopathy progression in type 2 diabetes","volume":"363","author":"Chew","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.preteyeres.2025.101406_bib51","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1038\/s41433-022-02136-w","article-title":"Subthreshold laser therapy guidelines for retinal diseases","volume":"36","author":"Chhablani","year":"2022","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.preteyeres.2025.101406_bib52","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/APO.0000000000000312","article-title":"Diabetic macular edema management in Asian population: expert panel consensus guidelines. Asia pac","volume":"9","author":"Chhablani","year":"2020","journal-title":"J Ophthalmol (Phila)"},{"key":"10.1016\/j.preteyeres.2025.101406_bib53","doi-asserted-by":"crossref","first-page":"S258","DOI":"10.2337\/dc24-S014","article-title":"Standards of care in Diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.preteyeres.2025.101406_bib54","doi-asserted-by":"crossref","first-page":"251","DOI":"10.4103\/tjo.tjo_31_20","article-title":"Combined intravitreal ranibizumab and posterior subtenon triamcinolone acetonide injections for patients with diabetic macular edema refractory to intravitreal ranibizumab monotherapy","volume":"11","author":"Chiu","year":"2021","journal-title":"Taiwan Journal of Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101406_bib55","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3341\/kjo.2006.20.4.205","article-title":"Intravitreal versus posterior subtenon injection of triamcinolone acetonide for diabetic macular edema","volume":"20","author":"Choi","year":"2006","journal-title":"Kor. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib56","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ophtha.2015.10.001","article-title":"Risk factors and incidence of macular edema after cataract surgery: a database study of 81984 eyes","volume":"123","author":"Chu","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101406_bib57","first-page":"3","article-title":"Diabetic retinopathy in the Asia-Pacific","volume":"7","author":"Chua","year":"2018","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"10.1016\/j.preteyeres.2025.101406_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.apjo.2024.100071","article-title":"Cost-effectiveness of diabetic retinopathy screening for newly diagnosed type 2 diabetic patients: a nationwide population-based propensity score-matched cohort study","volume":"13","author":"Chung","year":"2024","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"10.1016\/j.preteyeres.2025.101406_bib59","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/bjophthalmol-2020-315933","article-title":"Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes","volume":"105","author":"Ciulla","year":"2021","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib60","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ajo.2016.02.004","article-title":"Dexamethasone intravitreal implant for diabetic macular edema during pregnancy","volume":"165","author":"Concillado","year":"2016","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib61","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005708","article-title":"In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous","volume":"5","author":"Dalkara","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.preteyeres.2025.101406_bib62","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1001\/jamaophthalmol.2017.6256","article-title":"Disorganization of inner retina and outer retinal morphology in diabetic macular edema","volume":"136","author":"Das","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.preteyeres.2025.101406_bib63","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.ajo.2004.01.008","article-title":"Serum levels of triamcinolone acetonide after intravitreal injection","volume":"137","author":"Degenring","year":"2004","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib64","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2013.12.002","article-title":"Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies","volume":"67","author":"Diamond","year":"2014","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib65","unstructured":"Do, D.V., Aflibercept 8 mg in DME: Key results from the PHOTON extension study. Presented at the American Academy of Ophthalmology (AAO) 2024 Meeting. Chicago, Illinois."},{"key":"10.1016\/j.preteyeres.2025.101406_bib66","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/j.1464-5491.2005.01527.x","article-title":"Prevalence of diabetes complications 6 years after diagnosis in an incident cohort of childhood diabetes","volume":"22","author":"Donaghue","year":"2005","journal-title":"Diabet. Med."},{"key":"10.1016\/j.preteyeres.2025.101406_bib67","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1177\/1120672120915169","article-title":"Subthreshold yellow micropulse laser for treatment of diabetic macular edema: Comparison between fixed and variable treatment regimen","volume":"31","author":"Donati","year":"2021","journal-title":"Eur. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib68","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s40123-023-00829-3","article-title":"Intravitreal aflibercept for the treatment of diabetic macular edema in routine clinical practice: results from the 24-Month AURIGA observational study","volume":"13","author":"Donati","year":"2024","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.preteyeres.2025.101406_bib69","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0161-6420(13)38013-0","article-title":"Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11","volume":"98","year":"1991","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101406_bib70","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1001\/archopht.1990.01070090060040","article-title":"Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Four-year results of a randomized trial: diabetic retinopathy vitrectomy study report 5","volume":"108","year":"1990","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib71","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1097\/IAE.0000000000001266","article-title":"Structural-functional correlation in patients with diabetic macular edema","volume":"37","author":"Edington","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.preteyeres.2025.101406_bib72","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1080\/17425255.2017.1404987","article-title":"Pharmacokinetics of intravitreal anti-VEGF drugs in vitrectomized versus non-vitrectomized eyes","volume":"13","author":"Edington","year":"2017","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib73","first-page":"1","volume":"12","year":"1994","journal-title":"NIH Consens. Statement"},{"key":"10.1016\/j.preteyeres.2025.101406_bib74","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.2337\/diacare.23.8.1084","article-title":"Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The diabetes control and complications trial research group","volume":"23","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.preteyeres.2025.101406_bib75","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.oret.2017.07.004","article-title":"A prospective randomized comparative dosing trial of ranibizumab in bevacizumab-resistant diabetic macular edema: the REACT study","volume":"2","author":"Ehlers","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.preteyeres.2025.101406_bib76","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/1120672118782102","article-title":"Diabetic macular edema treated with ranibizumab following bevacizumab failure in Israel (DERBI study)","volume":"29","author":"Ehrlich","year":"2019","journal-title":"Eur. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib77","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ophtha.2010.02.031","article-title":"Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema","volume":"117","author":"Elman","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101406_bib78","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ophtha.2010.12.033","article-title":"Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema","volume":"118","author":"Elman","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101406_bib79","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ophtha.2014.08.047","article-title":"Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results","volume":"122","author":"Elman","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101406_bib80","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4274\/tjo.galenos.2019.91962","article-title":"Relationship between final visual acuity and optical coherence tomography findings in patients with diabetic macular edema undergoing anti-VEGF therapy","volume":"50","author":"Eraslan","year":"2020","journal-title":"Turk J Ophthalmol"},{"key":"10.1016\/j.preteyeres.2025.101406_bib81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40135-020-00225-1","article-title":"A new approach for diabetic macular edema treatment: review of clinical practice results with 0.19 mg fluocinolone acetonide intravitreal implant including vitrectomized eyes","volume":"8","author":"Estebainha","year":"2020","journal-title":"Curr Ophthalmol Rep"},{"key":"10.1016\/j.preteyeres.2025.101406_bib82","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11892-019-1188-4","article-title":"Treatment of diabetic macular edema","volume":"19","author":"Kim","year":"2019","journal-title":"Curr. Diabetes Rep."},{"key":"10.1016\/j.preteyeres.2025.101406_bib83","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000504753","article-title":"One-year results of treatment of diabetic macular edema with aflibercept using the treat-and-extend dosing regimen: the VIBIM study","volume":"243","author":"Pak","year":"2020","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.preteyeres.2025.101406_bib84","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2147\/OPTH.S14584","article-title":"Off-label use of intravitreal triamcinolone acetonide for diabetic macular edema in a pregnant patient","volume":"5","author":"Fazelat","year":"2011","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3928\/23258160-20161031-07","article-title":"Ranibizumab 0.3 mg for persistent diabetic macular edema after recent, frequent, and chronic bevacizumab: the ROTATE trial","volume":"47","author":"Fechter","year":"2016","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.preteyeres.2025.101406_bib86","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1097\/IAE.0b013e3181e7974f","article-title":"Factors associated with visual acuity outcomes after vitrectomy for diabetic macular edema: diabetic retinopathy clinical research network","volume":"30","author":"Flaxel","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.preteyeres.2025.101406_bib87","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1111\/j.1755-3768.2009.01773.x","article-title":"Investigation of the role of neutralizing antibodies against bevacizumab as mediators of tachyphylaxis","volume":"89","author":"Forooghian","year":"2011","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib88","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.ophtha.2004.11.045","article-title":"Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema","volume":"112","author":"Funatsu","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101406_bib89","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ophtha.2008.09.037","article-title":"Association of vitreous inflammatory factors with diabetic macular edema","volume":"116","author":"Funatsu","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101406_bib90","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/4896036","article-title":"Combined phacoemulsification and intravitreal dexamethasone implant (Ozurdex(R)) in diabetic patients with coexisting cataract and diabetic macular edema","volume":"2017","author":"Furino","year":"2017","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.preteyeres.2025.101406_bib91","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1038\/eye.2017.53","article-title":"Action on diabetic macular oedema: achieving optimal patient management in treating visual impairment due to diabetic eye disease","volume":"31","author":"Gale","year":"2017","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.preteyeres.2025.101406_bib92","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.oret.2021.05.002","article-title":"Machine learning can predict Anti-VEGF treatment demand in a treat-and-extend regimen for patients with neovascular AMD, DME, and RVO associated macular edema","volume":"5","author":"Gallardo","year":"2021","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.preteyeres.2025.101406_bib93","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3390\/pharmaceutics11080365","article-title":"Pharmacokinetics of intravitreal Anti-VEGF drugs in age-related macular degeneration","volume":"11","author":"Garc\u00eda-Quintanilla","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.preteyeres.2025.101406_bib94","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1007\/s12325-022-02119-z","article-title":"Dosing regimens of intravitreal aflibercept for diabetic macular edema beyond the first year: VIOLET, a prospective randomized trial","volume":"39","author":"Garweg","year":"2022","journal-title":"Adv. Ther."},{"key":"10.1016\/j.preteyeres.2025.101406_bib95","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/jcm8020242","article-title":"Micropulse laser treatment of retinal diseases","volume":"8","author":"Gaw\u0119cki","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.preteyeres.2025.101406_bib96","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/2561251","article-title":"Effectiveness of intravitreal ranibizumab in nonvitrectomized and vitrectomized eyes with diabetic macular edema: a two-year retrospective analysis","volume":"2020","author":"Gedar Totuk","year":"2020","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.preteyeres.2025.101406_bib97","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1089\/jop.2021.0001","article-title":"Comprehensive preclinical assessment of ADVM-022, an intravitreal Anti-VEGF gene therapy for the treatment of neovascular AMD and diabetic macular edema","volume":"37","author":"Gelfman","year":"2021","journal-title":"J. Ocul. Pharmacol. Therapeut."},{"key":"10.1016\/j.preteyeres.2025.101406_bib98","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/939748","article-title":"Retinal damage induced by internal limiting membrane removal","volume":"2015","author":"Gelman","year":"2015","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.preteyeres.2025.101406_bib99","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/bjophthalmol-2017-310483","article-title":"Predictive imaging biomarkers relevant for functional and anatomical outcomes during ranibizumab therapy of diabetic macular oedema","volume":"102","author":"Gerendas","year":"2018","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib100","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.4103\/ijo.IJO_1469_21","article-title":"Diabetic macular edema treatment guidelines in India: all India ophthalmological society diabetic retinopathy task force and vitreoretinal society of India consensus statement","volume":"69","author":"Giridhar","year":"2021","journal-title":"Indian J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib101","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1001\/jamaophthalmol.2019.6035","article-title":"Assessment of the DRCR retina network approach to management with initial observation for eyes with center-involved diabetic macular edema and good visual acuity: a secondary analysis of a randomized clinical trial","volume":"138","author":"Glassman","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.preteyeres.2025.101406_bib102","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.ophtha.2020.03.021","article-title":"Five-year outcomes after initial aflibercept, bevacizumab, or ranibizumab treatment for diabetic macular edema (protocol T extension study)","volume":"127","author":"Glassman","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101406_bib103","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/ceo.13764","article-title":"Dealing with co-existent cataract and diabetic macular oedema: an increasingly common conundrum now solved?","volume":"48","author":"Goh","year":"2020","journal-title":"Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib104","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/939315","article-title":"Costs and quality of life in diabetic macular edema: canadian burden of diabetic macular edema observational study (C-REALITY)","volume":"2014","author":"Gonder","year":"2014","journal-title":"J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib105","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40942-023-00453-0","article-title":"Predictive factors for treatment outcomes with intravitreal anti-vascular endothelial growth factor injections in diabetic macular edema in clinical practice","volume":"9","author":"Gurung","year":"2023","journal-title":"Int J Retina Vitreous"},{"key":"10.1016\/j.preteyeres.2025.101406_bib106","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.ophtha.2009.10.040","article-title":"Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction","volume":"117","author":"Haller","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101406_bib107","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1016\/j.ophtha.2016.07.032","article-title":"Intravitreal aflibercept for diabetic macular edema: 148-Week results from the VISTA and VIVID studies","volume":"123","author":"Heier","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101406_bib108","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/8035013","article-title":"Switching to aflibercept in diabetic macular edema not responding to ranibizumab and\/or intravitreal dexamethasone implant","volume":"2017","author":"Herbaut","year":"2017","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.preteyeres.2025.101406_bib109","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S0022-3476(98)70305-1","article-title":"Diabetic retinopathy in pediatric patients with type-1 diabetes: effect of diabetes duration, prepubertal and pubertal onset of diabetes, and metabolic control","volume":"132","author":"Holl","year":"1998","journal-title":"J. Pediatr."},{"key":"10.1016\/j.preteyeres.2025.101406_bib110","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ophtha.2021.04.031","article-title":"Efficacy and safety of biosimilar FYB201 compared with ranibizumab in neovascular age-related macular degeneration","volume":"129","author":"Holz","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101406_bib111","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-26048-7","article-title":"Genome-wide association study of the response of patients with diabetic macular edema to intravitreal Anti-VEGF injection","volume":"12","author":"Hong","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.preteyeres.2025.101406_bib112","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jamaophthalmol.2017.5202","article-title":"Association of abnormal renal profiles and proliferative diabetic retinopathy and diabetic macular edema in an Asian population with type 2 diabetes","volume":"136","author":"Hsieh","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.preteyeres.2025.101406_bib113","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1136\/bjophthalmol-2014-306492","article-title":"Prevalence and determinants of undiagnosed diabetic retinopathy and vision-threatening retinopathy in a multiethnic Asian cohort: the Singapore Epidemiology of eye diseases (SEED) study","volume":"99","author":"Huang","year":"2015","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib114","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1167\/iovs.65.14.46","article-title":"Real-world outcomes after switch from aflibercept to faricimab in eyes with diabetic macular edema","volume":"65","author":"Huber","year":"2024","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2025.101406_bib115","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/APO.0000000000000468","article-title":"Optical coherence tomography classification systems for diabetic macular edema and their associations with visual outcome and treatment responses - an updated review","volume":"11","author":"Hui","year":"2022","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"10.1016\/j.preteyeres.2025.101406_bib116","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1001\/jamaophthalmol.2019.4284","article-title":"Five-year cost-effectiveness of intravitreous ranibizumab therapy vs panretinal photocoagulation for treating proliferative diabetic retinopathy: a secondary analysis of a randomized clinical trial","volume":"137","author":"Hutton","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.preteyeres.2025.101406_bib117","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/ICB.0000000000000825","article-title":"Ranibizumab 0.5 MG treatment in adolescents with choroidal neovascularization: subgroup analysis data from the minerva study","volume":"15","author":"Hykin","year":"2021","journal-title":"Retin. Cases Brief Rep."},{"key":"10.1016\/j.preteyeres.2025.101406_bib118","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41433-022-01931-9","article-title":"Vitrectomized vs non-vitrectomized eyes in DEX implant treatment for DMO-Is there any difference? The VITDEX study","volume":"37","author":"Iglicki","year":"2023","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.preteyeres.2025.101406_bib119","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.ajo.2004.05.028","article-title":"Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injection","volume":"138","author":"Inoue","year":"2004","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib120","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1007\/s00417-005-1150-9","article-title":"Vitreous collagen metabolism before and after vitrectomy","volume":"243","author":"Itakura","year":"2005","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib121","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1097\/IAE.0000000000001280","article-title":"Pars plana vitrectomy for diabetic macular edema: a systematic review, meta-analysis, and synthesis of safety literature","volume":"37","author":"Jackson","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.preteyeres.2025.101406_bib122","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12886-024-03291-2","article-title":"Comparison of intravitreal preservative-free triamcinolone versus posterior sub-tenon triamcinolone acetonide injection for bevacizumab-resistant diabetic macular edema","volume":"24","author":"Jeon","year":"2024","journal-title":"BMC Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib123","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/S0002-9394(00)00575-4","article-title":"Perifoveal microcirculation before and after vitrectomy for diabetic cystoid macular edema","volume":"130","author":"Kadonosono","year":"2000","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib124","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0002-9394(00)00872-2","article-title":"Macular traction detachment and diabetic macular edema associated with posterior hyaloidal traction","volume":"131","author":"Kaiser","year":"2001","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib125","first-page":"1753","article-title":"Prospective randomised clinical trial of intravitreal bevacizumab versus triamcinolone in eyes with diabetic macular oedema undergoing cataract surgery: 6-Month results","volume":"103","author":"Kandasamy","year":"2019","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib126","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ajo.2003.09.016","article-title":"The correlation between fluorescein angiographic and optical coherence tomographic features in clinically significant diabetic macular edema","volume":"137","author":"Kang","year":"2004","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib127","first-page":"229","article-title":"Intravitreal ranibizumab versus intravitreal ranibizumab combined with posterior subtenon triamcinolone acetonide in diabetic macular edema","volume":"6","author":"Karatas","year":"2021","journal-title":"Beyoglu Eye J"},{"key":"10.1016\/j.preteyeres.2025.101406_bib128","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.preteyeres.2025.101406_bib129","first-page":"1343","article-title":"Insulin resistance, glucose intolerance and diabetes mellitus in obstructive sleep apnoea","volume":"7","author":"Kent","year":"2015","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.preteyeres.2025.101406_bib130","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1001\/jamaophthalmol.2025.0006","article-title":"Continuous ranibizumab via port delivery system vs monthly ranibizumab for treatment of diabetic macular edema: the pagoda randomized clinical trial","volume":"143","author":"Khanani","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.preteyeres.2025.101406_bib131","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ajo.2006.04.023","article-title":"Optical coherence tomographic patterns of diabetic macular edema","volume":"142","author":"Kim","year":"2006","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib132","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jcrs.2008.01.018","article-title":"Effect of a single intraoperative sub-tenon injection of triamcinolone acetonide on the progression of diabetic retinopathy and visual outcomes after cataract surgery","volume":"34","author":"Kim","year":"2008","journal-title":"J. Cataract Refract. Surg."},{"key":"10.1016\/j.preteyeres.2025.101406_bib133","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1167\/iovs.66.6.2","article-title":"Several common genetic variations associate with functional or anatomic effects of Anti-VEGF treatment in conditions with macular edema","volume":"66","author":"Klaassen","year":"2025","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2025.101406_bib134","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2337\/diacare.13.1.34","article-title":"Effect of pregnancy on progression of diabetic retinopathy","volume":"13","author":"Klein","year":"1990","journal-title":"Diabetes Care"},{"key":"10.1016\/j.preteyeres.2025.101406_bib135","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3109\/09286589509071451","article-title":"Older-onset diabetes and lens opacities. The beaver dam eye study","volume":"2","author":"Klein","year":"1995","journal-title":"Ophthalmic Epidemiol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib136","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0002-9394(14)71170-5","article-title":"Incidence of cataract surgery in the Wisconsin epidemiologic study of diabetic retinopathy","volume":"119","author":"Klein","year":"1995","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib137","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0002-9394(98)00280-3","article-title":"Diabetes, cardiovascular disease, selected cardiovascular disease risk factors, and the 5-year incidence of age-related cataract and progression of lens opacities: the beaver dam eye study","volume":"126","author":"Klein","year":"1998","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib138","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3109\/09273948.2015.1034804","article-title":"Serum and aqueous concentrations of inflammatory markers in diabetic macular edema","volume":"24","author":"Kocabora","year":"2016","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.preteyeres.2025.101406_bib139","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics13010072","article-title":"Real-world efficacy and safety of fluocinolone acetonide implant for diabetic macular edema: a systematic review","volume":"13","author":"Kodjikian","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.preteyeres.2025.101406_bib140","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1038\/s41433-025-03692-7","article-title":"What have we learned from a decade treating patients with diabetic macular oedema with 0.19 mg fluocinolone acetonide intravitreal implant?","volume":"39","author":"Kodjikian","year":"2025","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.preteyeres.2025.101406_bib141","first-page":"296","article-title":"Recommended guidelines for use of intravitreal aflibercept with a treat-and-extend regimen for the management of neovascular age-related macular degeneration in the Asia-Pacific region: report from a consensus panel","volume":"6","author":"Koh","year":"2017","journal-title":"Asia Pac. J. Ophthalmol. (Phila)"},{"key":"10.1016\/j.preteyeres.2025.101406_bib142","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nrc1122","article-title":"Occurrence of leukaemia following gene therapy of X-linked SCID","volume":"3","author":"Kohn","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.preteyeres.2025.101406_bib143","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1038\/eye.2017.122","article-title":"Clinical real-world results of switching treatment from ranibizumab to aflibercept in patients with diabetic macular oedema","volume":"31","author":"Konidaris","year":"2017","journal-title":"Eye"},{"key":"10.1016\/j.preteyeres.2025.101406_bib144","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","article-title":"Intravitreal aflibercept for diabetic macular edema","volume":"121","author":"Korobelnik","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101406_bib145","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000446992","article-title":"Comparison of the effectiveness of intravitreal ranibizumab for diabetic macular edema in vitrectomized and nonvitrectomized eyes","volume":"236","author":"Koyanagi","year":"2016","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.preteyeres.2025.101406_bib146","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.oret.2024.05.017","article-title":"Long-term treatment patterns for diabetic macular edema: up to 6-Year Follow-up in the IRIS\u00ae registry","volume":"8","author":"Kuo","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.preteyeres.2025.101406_bib147","first-page":"83","volume":"vol. 256","author":"Laiginhas","year":"2018"},{"key":"10.1016\/j.preteyeres.2025.101406_bib148","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1442-9071.2004.00903.x","article-title":"Intravitreal triamcinolone for diabetic macular oedema in Chinese patients: six-month prospective longitudinal pilot study","volume":"32","author":"Lam","year":"2004","journal-title":"Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib149","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/sj.eye.6701686","article-title":"Phacoemulsification with intravitreal triamcinolone in patients with cataract and coexisting diabetic macular oedema: a 6-month prospective pilot study","volume":"19","author":"Lam","year":"2005","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.preteyeres.2025.101406_bib150","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/bjo.2006.102848","article-title":"A prospective randomised trial of different doses of intravitreal triamcinolone for diabetic macular oedema","volume":"91","author":"Lam","year":"2007","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib151","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/IAE.0b013e31819a2d61","article-title":"Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial","volume":"29","author":"Lam","year":"2009","journal-title":"Retina"},{"key":"10.1016\/j.preteyeres.2025.101406_bib152","doi-asserted-by":"crossref","first-page":"304","DOI":"10.2337\/dc23-0993","article-title":"Performance of artificial intelligence in detecting diabetic macular edema from fundus photography and optical coherence tomography images: a systematic review and meta-analysis","volume":"47","author":"Lam","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.preteyeres.2025.101406_bib153","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1442-9071.2010.02256.x","article-title":"Prevalence and associations of diabetic retinopathy in Indigenous Australians within central Australia: the central Australian ocular health study","volume":"38","author":"Landers","year":"2010","journal-title":"Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib154","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00592-020-01506-8","article-title":"Fundamental principles of an effective diabetic retinopathy screening program","volume":"57","author":"Lanzetta","year":"2020","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib155","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41433-018-0297-7","article-title":"Cost-effectiveness of digital surveillance clinics with optical coherence tomography versus hospital eye service follow-up for patients with screen-positive maculopathy","volume":"33","author":"Leal","year":"2019","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.preteyeres.2025.101406_bib156","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1089\/jop.2016.0074","article-title":"Short-term outcomes of switching to ranibizumab therapy for diabetic macular edema in patients with persistent fluid after bevacizumab therapy","volume":"32","author":"Lee","year":"2016","journal-title":"J. Ocul. Pharmacol. Therapeut."},{"key":"10.1016\/j.preteyeres.2025.101406_bib157","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/APO.0000000000000583","article-title":"Application of artificial intelligence in precision medicine for diabetic macular edema","volume":"12","author":"Li","year":"2023","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"10.1016\/j.preteyeres.2025.101406_bib158","doi-asserted-by":"crossref","DOI":"10.1016\/j.apjo.2024.100109","article-title":"Current research and future strategies for the management of vision-threatening diabetic retinopathy","volume":"13","author":"Li","year":"2024","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"10.1016\/j.preteyeres.2025.101406_bib159","doi-asserted-by":"crossref","DOI":"10.1016\/j.apjo.2024.100096","article-title":"Artificial intelligence for retinal diseases","volume":"13","author":"Lim","year":"2024","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"10.1016\/j.preteyeres.2025.101406_bib160","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2025-002178","article-title":"Anti-VEGF treatment switch in real-world DME patients: ranibizumab versus aflibercept for bevacizumab DME non-responding patients (SWIRL study)","volume":"10","author":"Lim","year":"2025","journal-title":"BMJ Open Ophthalmol"},{"key":"10.1016\/j.preteyeres.2025.101406_bib161","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11892-021-01436-x","article-title":"Pediatric diabetic retinopathy: updates in prevalence, risk factors, screening, and management","volume":"21","author":"Lin","year":"2021","journal-title":"Curr. Diabetes Rep."},{"key":"10.1016\/j.preteyeres.2025.101406_bib162","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.oret.2021.12.021","article-title":"Deep learning to detect OCT-Derived diabetic macular edema from color retinal photographs: a multicenter validation study","volume":"6","author":"Liu","year":"2022","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.preteyeres.2025.101406_bib163","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.survophthal.2022.04.001","article-title":"Switching between anti-VEGF agents in the management of refractory diabetic macular edema: a systematic review","volume":"67","author":"Madjedi","year":"2022","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib164","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/00006982-199313020-00006","article-title":"Foveal avascular zone in diabetes mellitus","volume":"13","author":"Mansour","year":"1993","journal-title":"Retina"},{"key":"10.1016\/j.preteyeres.2025.101406_bib165","first-page":"130","article-title":"Diabetic macular edema: from old concepts to new therapeutic avenues","volume":"4","author":"Mansour","year":"2015","journal-title":"Med. Hypothesis, Discov. Innovation (MEHDI) Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib166","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S2352-4642(21)00195-4","article-title":"2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial","volume":"5","author":"Marlow","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.preteyeres.2025.101406_bib167","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102567","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): five-year outcomes of a randomised trial","volume":"71","author":"Marlow","year":"2024","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.preteyeres.2025.101406_bib168","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.2337\/dc10-0493","article-title":"Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II study","volume":"33","author":"Massin","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.preteyeres.2025.101406_bib169","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1159\/000511591","article-title":"Real-world outcomes after 36-Month treatment with ranibizumab 0.5 mg in patients with visual impairment due to diabetic macular edema (BOREAL-DME)","volume":"64","author":"Massin","year":"2021","journal-title":"Ophthalmic Res."},{"key":"10.1016\/j.preteyeres.2025.101406_bib170","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-014444","article-title":"Population trends in the 10-year incidence and prevalence of diabetic retinopathy in the UK: a cohort study in the clinical practice research datalink 2004-2014","volume":"7","author":"Mathur","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.preteyeres.2025.101406_bib171","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1097\/IAE.0000000000001004","article-title":"Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-YEAR MEAD study","volume":"36","author":"Maturi","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.preteyeres.2025.101406_bib172","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamaophthalmol.2017.4914","article-title":"Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR network phase 2 randomized clinical trial","volume":"136","author":"Maturi","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.preteyeres.2025.101406_bib173","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.ophtha.2010.03.045","article-title":"A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2","volume":"117","author":"Michaelides","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101406_bib174","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.preteyeres.2025.101406_bib175","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ophtha.2011.01.031","article-title":"The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema","volume":"118","author":"Mitchell","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101406_bib176","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1136\/bjophthalmol-2011-300726","article-title":"Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial","volume":"96","author":"Mitchell","year":"2012","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib177","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0233595","article-title":"Effectiveness and safety of ranibizumab 0.5 mg in treatment-na\u00efve patients with diabetic macular edema: results from the real-world global LUMINOUS study","volume":"15","author":"Mitchell","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.preteyeres.2025.101406_bib178","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.joco.2016.09.007","article-title":"Vitrectomy for diabetic macular edema; where are we?","volume":"28","author":"Modarres","year":"2016","journal-title":"J Curr Ophthalmol"},{"key":"10.1016\/j.preteyeres.2025.101406_bib179","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/j.1442-9071.2009.02104.x","article-title":"Factors associated with variability in response of diabetic macular oedema after intravitreal triamcinolone","volume":"37","author":"Mohamed","year":"2009","journal-title":"Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib180","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/ceo.12760","article-title":"Diabetic retinopathy in pregnancy: a review","volume":"44","author":"Morrison","year":"2016","journal-title":"Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib181","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1007\/s00125-017-4314-3","article-title":"Improved pregnancy outcomes in women with type 1 and type 2 diabetes but substantial clinic-to-clinic variations: a prospective nationwide study","volume":"60","author":"Murphy","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.preteyeres.2025.101406_bib182","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1001\/jama.2008.656","article-title":"Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis","volume":"300","author":"Nalluri","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.preteyeres.2025.101406_bib183","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1038\/s41598-024-54109-6","article-title":"Comparison of retinal thickness measurements among four different optical coherence tomography devices","volume":"14","author":"Nam","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.preteyeres.2025.101406_bib184","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Nathan","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.preteyeres.2025.101406_bib185","doi-asserted-by":"crossref","DOI":"10.1038\/srep45081","article-title":"Elevated angiopoietin 2 in aqueous of patients with neovascular age related macular degeneration correlates with disease severity at presentation","volume":"7","author":"Ng","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.preteyeres.2025.101406_bib186","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1016\/j.ophtha.2010.08.016","article-title":"Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study","volume":"117","author":"Nguyen","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101406_bib187","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101406_bib188","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/jcm14093205","article-title":"Gene therapy in diabetic retinopathy and diabetic macular edema: an update","volume":"14","author":"Odio-Herrera","year":"2025","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.preteyeres.2025.101406_bib189","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1109\/JBHI.2019.2929842","article-title":"Automated quantification of hyperreflective foci in SD-OCT with diabetic retinopathy","volume":"24","author":"Okuwobi","year":"2020","journal-title":"IEEE J Biomed Health Inform"},{"key":"10.1016\/j.preteyeres.2025.101406_bib190","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S1056-8727(03)00073-4","article-title":"The significance of the prepubertal diabetes duration for the development of retinopathy and nephropathy in patients with type 1 diabetes","volume":"18","author":"Olsen","year":"2004","journal-title":"J. Diabet. Complicat."},{"key":"10.1016\/j.preteyeres.2025.101406_bib191","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1016\/j.ophtha.2017.03.066","article-title":"Incidence and risk factors for developing diabetic retinopathy among youths with type 1 or type 2 diabetes throughout the United States (ophthalmology. 2017;124:424-430)","volume":"124","author":"Olsen","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101406_bib192","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1167\/iovs.17-23304","article-title":"Importance of considering the middle capillary plexus on OCT angiography in diabetic retinopathy","volume":"59","author":"Onishi","year":"2018","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2025.101406_bib193","doi-asserted-by":"crossref","first-page":"5619","DOI":"10.1038\/s41598-020-62329-9","article-title":"Automated quantification of photoreceptor alteration in macular disease using optical coherence tomography and deep learning","volume":"10","author":"Orlando","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.preteyeres.2025.101406_bib194","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0002-9394(99)00033-1","article-title":"Patterns of diabetic macular edema with optical coherence tomography","volume":"127","author":"Otani","year":"1999","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib195","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1210\/clinem\/dgad581","article-title":"Diabetic macular edema is predictive of renal failure in patients with diabetes mellitus and chronic kidney disease","volume":"109","author":"Ou","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.preteyeres.2025.101406_bib196","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jdiacomp.2005.06.015","article-title":"Posterior subtenon and intravitreal triamcinolone acetonide for diabetic macular edema","volume":"20","author":"\u00d6zdek","year":"2006","journal-title":"J. Diabetes Complicat."},{"key":"10.1016\/j.preteyeres.2025.101406_bib197","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.preteyeres.2025.101406_bib198","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/08820530490519934","article-title":"Diabetic macular edema: an OCT-Based classification","volume":"19","author":"Panozzo","year":"2004","journal-title":"Semin. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib199","doi-asserted-by":"crossref","first-page":"433","DOI":"10.5301\/ejo.5000920","article-title":"Dexamethasone intravitreal implant at the time of cataract surgery in eyes with diabetic macular edema","volume":"27","author":"Panozzo","year":"2017","journal-title":"Eur. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib200","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","article-title":"Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap, ranibizumab and bevacizumab","volume":"15","author":"Papadopoulos","year":"2012","journal-title":"Angiogenesis"},{"key":"10.1016\/j.preteyeres.2025.101406_bib201","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3928\/23258160-20160419-05","article-title":"Characterization of intraocular pressure increases and management strategies following treatment with fluocinolone acetonide intravitreal implants in the FAME trials","volume":"47","author":"Parrish","year":"2016","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.preteyeres.2025.101406_bib202","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40942-020-00268-3","article-title":"Real-life outcomes of subthreshold laser therapy for diabetic macular edema","volume":"7","author":"Passos","year":"2021","journal-title":"Int J Retina Vitreous"},{"key":"10.1016\/j.preteyeres.2025.101406_bib203","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ophtha.2016.09.021","article-title":"Randomized trial of treat and extend ranibizumab with and without navigated laser for diabetic macular edema: TREX-DME 1 year outcomes","volume":"124","author":"Payne","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101406_bib204","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/j.ophtha.2015.05.038","article-title":"Ranibizumab 0.5 mg for diabetic macular edema with bimonthly monitoring after a phase of initial treatment: 18-Month, multicenter, phase IIIB RELIGHT study","volume":"122","author":"Pearce","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101406_bib205","first-page":"9","article-title":"Focal laser photocoagulation in non-center involved diabetic macular edema","volume":"3","author":"Perente","year":"2014","journal-title":"Med. Hypothesis, Discov. Innovation (MEHDI) Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib206","doi-asserted-by":"crossref","unstructured":"Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Early treatment diabetic retinopathy study research group. 1985. Arch. Ophthalmol. 103, 1796\u20131806.","DOI":"10.1001\/archopht.1985.01050120030015"},{"issue":"Suppl. 9","key":"10.1016\/j.preteyeres.2025.101406_bib207","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1399-5448.2007.00330.x","article-title":"Clinical presentation and treatment of type 2 diabetes in children","volume":"8","author":"Pinhas-Hamiel","year":"2007","journal-title":"Pediatr. Diabetes"},{"key":"10.1016\/j.preteyeres.2025.101406_bib208","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/bjophthalmol-2016-308617","article-title":"Prospective randomised clinical trial to evaluate the safety and efficacy of nepafenac 0.1% treatment for the prevention of macular oedema associated with cataract surgery in patients with diabetic retinopathy","volume":"101","author":"Pollack","year":"2017","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib209","doi-asserted-by":"crossref","first-page":"236","DOI":"10.4103\/IJO.IJO_2182_22","article-title":"Natural course of non-center-involving diabetic macular edema progression in patients under initial observation","volume":"72","author":"Pradhana","year":"2024","journal-title":"Indian J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib210","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1755-3768.2009.01661.x","article-title":"Vitreous and serum levels of vascular endothelial growth factor and platelet-derived growth factor and their correlation in patients with non-proliferative diabetic retinopathy and clinically significant macula oedema","volume":"89","author":"Praidou","year":"2011","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib211","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1136\/bjophthalmol-2015-307249","article-title":"Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study","volume":"100","author":"Pr\u00fcnte","year":"2016","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib212","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2025.101354","article-title":"Gene therapy-associated uveitis (GTAU): understanding and mitigating the adverse immune response in retinal gene therapy","volume":"106","author":"Purdy","year":"2025","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.preteyeres.2025.101406_bib213","first-page":"1020","article-title":"Sub-threshold micro-pulse diode laser treatment in diabetic macular edema: a meta-analysis of randomized controlled trials","volume":"9","author":"Qiao","year":"2016","journal-title":"Int. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib214","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1001\/jamaophthalmol.2015.0972","article-title":"Association of disorganization of retinal inner layers with vision after resolution of center-involved diabetic macular edema","volume":"133","author":"Radwan","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.preteyeres.2025.101406_bib215","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1038\/eye.2008.360","article-title":"The effect of intravitreal bevacizumab (Avastin) administration on systemic hypertension","volume":"23","author":"Rasier","year":"2009","journal-title":"Eye"},{"key":"10.1016\/j.preteyeres.2025.101406_bib216","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1007\/s00125-010-1697-9","article-title":"Progression of diabetic retinopathy during pregnancy in women with type 2 diabetes","volume":"53","author":"Rasmussen","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.preteyeres.2025.101406_bib217","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1080\/09273948.2018.1424342","article-title":"Safety and efficacy of intravitreal dexamethasone implant for refractory uveitic macular edema in adults and children","volume":"26","author":"Ratra","year":"2018","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.preteyeres.2025.101406_bib218","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1097\/IAE.0b013e31824bebb8","article-title":"Intravitreal injection of ranibizumab during cataract surgery in patients with diabetic macular edema","volume":"32","author":"Rauen","year":"2012","journal-title":"Retina"},{"key":"10.1016\/j.preteyeres.2025.101406_bib219","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ajo.2014.09.033","article-title":"Baseline choroidal thickness as a predictor for response to anti-vascular endothelial growth factor therapy in diabetic macular edema","volume":"159","author":"Rayess","year":"2015","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib220","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1136\/bjophthalmol-2019-314336","article-title":"Estimated number of ophthalmologists worldwide (international council of ophthalmology update): will we meet the needs?","volume":"104","author":"Resnikoff","year":"2020","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib221","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1001\/jamaophthalmol.2020.2457","article-title":"Quantification of fluid resolution and visual acuity gain in patients with diabetic macular edema using deep learning: a post hoc analysis of a randomized clinical trial","volume":"138","author":"Roberts","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.preteyeres.2025.101406_bib222","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2156273","article-title":"Diabetic macular edema pathophysiology: vasogenic versus inflammatory","volume":"2016","author":"Romero-Aroca","year":"2016","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.preteyeres.2025.101406_bib223","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jamaophthalmol.2016.1669","article-title":"Cost-effectiveness of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema treatment: analysis from the diabetic retinopathy clinical research network comparative effectiveness trial","volume":"134","author":"Ross","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.preteyeres.2025.101406_bib224","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41433-019-0747-x","article-title":"Recommendations by a UK expert panel on an aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration","volume":"34","author":"Ross","year":"2020","journal-title":"Eye (Lond)."},{"key":"10.1016\/j.preteyeres.2025.101406_bib225","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1076\/0928-6586(200006)721-ZFT103","article-title":"Diabetes, fasting blood glucose and age-related cataract: the Blue Mountains eye study","volume":"7","author":"Rowe","year":"2000","journal-title":"Ophthalmic Epidemiol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib226","doi-asserted-by":"crossref","DOI":"10.1016\/j.apjo.2025.100144","article-title":"Consensus and guidelines on diagnosis and management of polypoidal choroidal vasculopathy (PCV) from the Asia-Pacific Vitreo-retina society (APVRS)","volume":"14","author":"Ruamviboonsuk","year":"2025","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"10.1016\/j.preteyeres.2025.101406_bib227","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm12010274","article-title":"Subthreshold micropulse laser for diabetic macular edema: a review","volume":"12","author":"Sabal","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.preteyeres.2025.101406_bib228","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41433-019-0522-z","article-title":"Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: a post hoc analysis of protocol I data","volume":"34","author":"Sadda","year":"2020","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.preteyeres.2025.101406_bib229","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.4103\/ijo.IJO_1805_18","article-title":"Rapidly reversing bilateral macular edema associated with fluid overload in a young type 1 diabetic","volume":"67","author":"Samanta","year":"2019","journal-title":"Indian J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib230","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1167\/iovs.06-1102","article-title":"Progression of diabetic macular edema: correlation with blood retinal barrier permeability, retinal thickness, and retinal vessel diameter","volume":"48","author":"Sander","year":"2007","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2025.101406_bib231","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1080\/14656566.2018.1516206","article-title":"Pharmacotherapeutic management of macular edema in diabetic subjects undergoing cataract surgery","volume":"19","author":"Sarao","year":"2018","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.preteyeres.2025.101406_bib232","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity","volume":"153","author":"Sato","year":"2012","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib233","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1111\/dme.13263","article-title":"Risk of diabetic retinopathy at first screen in children at 12 and 13 years of age","volume":"33","author":"Scanlon","year":"2016","journal-title":"Diabet. Med."},{"key":"10.1016\/j.preteyeres.2025.101406_bib234","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/jnci\/djm086","article-title":"Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab","volume":"99","author":"Scappaticci","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.preteyeres.2025.101406_bib235","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1124\/pr.114.009423","article-title":"Neuro-bio-behavioral mechanisms of placebo and nocebo responses: implications for clinical trials and clinical practice","volume":"67","author":"Schedlowski","year":"2015","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.preteyeres.2025.101406_bib236","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ophtha.2017.10.031","article-title":"Fully automated detection and quantification of macular fluid in OCT using deep learning","volume":"125","author":"Schlegl","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101406_bib237","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000458539","article-title":"Guidelines for the management of diabetic macular edema by the european society of retina specialists (EURETINA)","volume":"237","author":"Schmidt-Erfurth","year":"2017","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.preteyeres.2025.101406_bib238","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/ICU.0b013e328333e9c1","article-title":"Cataract surgery and diabetes","volume":"21","author":"Shah","year":"2010","journal-title":"Curr. Opin. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib239","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40942-021-00293-w","article-title":"Safety and efficacy of razumab\u2122 (world's first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study","volume":"7","author":"Sharma","year":"2021","journal-title":"Int J Retina Vitreous"},{"key":"10.1016\/j.preteyeres.2025.101406_bib240","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jamaophthalmol.2021.1037","article-title":"Biosimilar ranibizumab (SB11) vs reference ranibizumab-diving deeper for safety and efficacy","volume":"139","author":"Sharma","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.preteyeres.2025.101406_bib241","author":"Sheth"},{"key":"10.1016\/j.preteyeres.2025.101406_bib242","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/JCMA.0000000000000680","article-title":"One-year outcomes of the treat-and-extend regimen using aflibercept for the treatment of diabetic macular edema","volume":"85","author":"Sheu","year":"2022","journal-title":"J. Chin. Med. Assoc."},{"key":"10.1016\/j.preteyeres.2025.101406_bib243","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00417-011-1774-x","article-title":"Association between photoreceptor integrity and visual outcome in diabetic macular edema","volume":"250","author":"Shin","year":"2012","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib244","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1007\/s40123-025-01172-5","article-title":"Revisiting the role of intravitreal triamcinolone in diabetic macular edema: 12-month outcomes after bevacizumab failure","volume":"14","author":"Silpa-Archa","year":"2025","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.preteyeres.2025.101406_bib245","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.ajo.2013.05.033","article-title":"Predictive factors for the progression of diabetic macular ischemia","volume":"156","author":"Sim","year":"2013","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib246","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ajo.2014.03.009","article-title":"Patterns of peripheral retinal and central macula ischemia in diabetic retinopathy as evaluated by ultra-widefield fluorescein angiography","volume":"158","author":"Sim","year":"2014","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib247","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0889-8529(05)70106-7","article-title":"Early diabetes-related complications in children and adolescents with type 1 diabetes. Implications for screening and intervention","volume":"28","author":"Sochett","year":"1999","journal-title":"Endocrinol Metab. Clin. N. Am."},{"key":"10.1016\/j.preteyeres.2025.101406_bib248","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ophtha.2015.09.002","article-title":"Intravitreal bevacizumab versus ranibizumab for treatment of neovascular age-related macular degeneration: findings from a cochrane systematic review","volume":"123","author":"Solomon","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101406_bib249","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.2147\/OPTH.S399981","article-title":"Characteristics and treatment patterns of patients with diabetic macular edema non-responsive to anti-vascular endothelial growth factor treatment in Ontario, Canada","volume":"17","author":"Somani","year":"2023","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib250","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/pharmaceutics15102461","article-title":"Intravitreal DEX implant for the treatment of diabetic macular edema: a review of national consensus","volume":"15","author":"Spinetta","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.preteyeres.2025.101406_bib251","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.preteyeres.2025.101406_bib252","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1001\/jama.2022.10564","article-title":"Effect of intravitreal aflibercept vs laser photocoagulation on treatment success of retinopathy of prematurity: the FIREFLEYE randomized clinical trial","volume":"328","author":"Stahl","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.preteyeres.2025.101406_bib253","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ajo.2021.06.030","article-title":"Fluctuations in central subfield thickness associated with worse visual outcomes in patients with diabetic macular edema in clinical trial setting","volume":"232","author":"Starr","year":"2021","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib254","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.ophtha.2013.02.002","article-title":"Cost-effectiveness of various interventions for newly diagnosed diabetic macular edema","volume":"120","author":"Stein","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101406_bib255","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1001\/jamaophthalmol.2014.2350","article-title":"Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with center-involved diabetic macular edema","volume":"132","author":"Sun","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.preteyeres.2025.101406_bib256","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.ophtha.2020.10.008","article-title":"Updating the staging system for diabetic retinal disease","volume":"128","author":"Sun","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101406_bib257","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41433-020-01233-y","article-title":"Optical coherence tomography angiography in diabetic retinopathy: an updated review","volume":"35","author":"Sun","year":"2021","journal-title":"Eye (Lond)."},{"key":"10.1016\/j.preteyeres.2025.101406_bib258","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/IAE.0000000000003730","article-title":"Defining \"strong\" versus \"weak\" response to antivascular endothelial growth factor treatment for center-involved diabetic macular edema","volume":"43","author":"Sun","year":"2023","journal-title":"Retina"},{"key":"10.1016\/j.preteyeres.2025.101406_bib259","article-title":"Comparison of retinal nerve fiber layer thickness measured by cirrus HD and stratus optical coherence tomography","volume":"116","author":"Sung","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101406_bib260","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/APO.0000000000000584","article-title":"Recent advances in clinical applications of imaging in retinal diseases","volume":"12","author":"Szeto","year":"2023","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"10.1016\/j.preteyeres.2025.101406_bib261","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2023.101220","article-title":"Optical coherence tomography in the management of diabetic macular oedema","volume":"98","author":"Szeto","year":"2024","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.preteyeres.2025.101406_bib262","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.ophtha.2009.01.014","article-title":"Analysis of the effect of intravitreal bevacizumab injection on diabetic macular edema after cataract surgery","volume":"116","author":"Takamura","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101406_bib263","article-title":"Diabetic retinopathy: looking forward to 2030","volume":"13","author":"Tan","year":"2022","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib264","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1038\/s41598-017-02767-0","article-title":"Determinants of quantitative optical coherence tomography angiography metrics in patients with diabetes","volume":"7","author":"Tang","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.preteyeres.2025.101406_bib265","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1097\/IAE.0b013e3181f57d58","article-title":"Intravitreal bevacizumab during pregnancy","volume":"30","author":"Tarantola","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.preteyeres.2025.101406_bib266","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","article-title":"Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis","volume":"128","author":"Teo","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101406_bib267","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1007\/s10792-017-0738-5","article-title":"VEGF-A gene polymorphisms and responses to intravitreal ranibizumab treatment in patients with diabetic macular edema","volume":"38","author":"Tetiko\u011flu","year":"2018","journal-title":"Int. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib268","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1001\/archopht.1995.01100010038019","article-title":"The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus","volume":"113","year":"1995","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib269","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1124\/jpet.119.262956","article-title":"Cytokines and growth factors as predictors of response to medical treatment in diabetic macular edema","volume":"373","author":"Torres-Costa","year":"2020","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.preteyeres.2025.101406_bib270","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1097\/IAE.0000000000002721","article-title":"Diabetic macular ischemia: correlation of retinal vasculature changes by optical coherence tomography angiography and functional deficit","volume":"40","author":"Tsai","year":"2020","journal-title":"Retina"},{"key":"10.1016\/j.preteyeres.2025.101406_bib271","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ophtha.2020.11.012","article-title":"Neurodevelopmental outcomes after bevacizumab treatment for retinopathy of prematurity: a meta-analysis","volume":"128","author":"Tsai","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101406_bib272","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10633-008-9120-2","article-title":"Multifocal electroretinogram (mfERG) in patients with diabetes mellitus and an enlarged foveal avascular zone (FAZ)","volume":"117","author":"Tyrberg","year":"2008","journal-title":"Doc. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib273","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.2147\/OPTH.S320948","article-title":"Challenges in diabetic macular edema management: an expert consensus report","volume":"15","author":"Udaondo","year":"2021","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib274","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: ukpds 38","volume":"317","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.preteyeres.2025.101406_bib275","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.preteyeres.2025.101406_bib276","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamaophthalmol.2023.2307","article-title":"Difficulty in assessing the systemic adverse effects of intravitreal anti-vascular endothelial growth factor therapy","volume":"141","author":"VanderBeek","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.preteyeres.2025.101406_bib277","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41467-019-13922-8","article-title":"Predicting optical coherence tomography-derived diabetic macular edema grades from fundus photographs using deep learning","volume":"11","author":"Varadarajan","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.preteyeres.2025.101406_bib278","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1464-5491.2010.02958.x","article-title":"Pregnancy-induced sight-threatening diabetic retinopathy in women with type 1 diabetes","volume":"27","author":"Vestgaard","year":"2010","journal-title":"Diabet. Med."},{"key":"10.1016\/j.preteyeres.2025.101406_bib279","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/IAE.0000000000001954","article-title":"Evaluation of obstructive sleep apnea syndrome as a risk factor for diabetic macular edema in patients with type II diabetes","volume":"39","author":"Vi\u00e9","year":"2019","journal-title":"Retina"},{"key":"10.1016\/j.preteyeres.2025.101406_bib280","first-page":"Cd007419","article-title":"Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis","volume":"6","author":"Virgili","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.preteyeres.2025.101406_bib281","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1097\/IAE.0b013e3181c96986","article-title":"Microperimetry and fundus autofluorescence in diabetic macular edema: Subthreshold micropulse diode laser versus modified early treatment diabetic retinopathy study laser photocoagulation","volume":"30","author":"Vujosevic","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.preteyeres.2025.101406_bib282","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.survophthal.2024.07.006","article-title":"Role of inflammation in diabetic macular edema and neovascular age-related macular degeneration","volume":"69","author":"Vujosevic","year":"2024","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib283","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jamaophthalmol.2020.0334","article-title":"Short-term outcomes after very low-dose intravitreous bevacizumab for retinopathy of prematurity","volume":"138","author":"Wallace","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.preteyeres.2025.101406_bib284","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/cells10051049","article-title":"Anti-VEGF-Resistant retinal diseases: a review of the latest treatment options","volume":"10","author":"Wallsh","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.preteyeres.2025.101406_bib285","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3109\/02713683.2012.675616","article-title":"Intravitreal ranibizumab (lucentis) for the treatment of diabetic macular edema: a systematic review and meta-analysis of randomized clinical control trials","volume":"37","author":"Wang","year":"2012","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.preteyeres.2025.101406_bib286","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/s41433-021-01672-1","article-title":"Fluctuations in macular thickness in patients with diabetic macular oedema treated with anti-vascular endothelial growth factor agents","volume":"36","author":"Wang","year":"2022","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.preteyeres.2025.101406_bib287","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema","volume":"372","author":"Wells","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.preteyeres.2025.101406_bib288","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial","volume":"123","author":"Wells","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101406_bib289","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.ophtha.2018.04.007","article-title":"Guidelines on diabetic eye care: the international council of ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings","volume":"125","author":"Wong","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101406_bib291","series-title":"Guidelines for the Management of Hypertension in Patients with Diabetes Mellitus: Quick Reference Guide","article-title":"Regional office for the eastern mediterranean","year":"2006"},{"key":"10.1016\/j.preteyeres.2025.101406_bib292","doi-asserted-by":"crossref","first-page":"143","DOI":"10.47102\/annals-acadmedsg.V39N2p143","article-title":"Inadvertent use of bevacizumab to treat choroidal neovascularisation during pregnancy: a case report","volume":"39","author":"Wu","year":"2010","journal-title":"Ann. Acad. Med. Singapore"},{"key":"10.1016\/j.preteyeres.2025.101406_bib293","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ajo.2016.09.029","article-title":"Outcomes with As-Needed aflibercept and macular laser following the phase III VISTA DME trial: ENDURANCE 12-Month extension study","volume":"173","author":"Wykoff","year":"2017","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib294","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1001\/jamaophthalmol.2017.0988","article-title":"Association of diabetic macular edema and proliferative diabetic retinopathy with cardiovascular disease: a systematic review and meta-analysis","volume":"135","author":"Xie","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.preteyeres.2025.101406_bib295","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1167\/tvst.9.2.21","article-title":"Fast and automated hyperreflective foci segmentation based on image enhancement and improved 3D U-Net in SD-OCT volumes with diabetic retinopathy","volume":"9","author":"Xie","year":"2020","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib296","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/IAE.0000000000000116","article-title":"Systemic safety of ranibizumab for diabetic macular edema: meta-analysis of randomized trials","volume":"34","author":"Yanagida","year":"2014","journal-title":"Retina"},{"key":"10.1016\/j.preteyeres.2025.101406_bib297","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/eye.2015.98","article-title":"Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants","volume":"29","author":"Yang","year":"2015","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.preteyeres.2025.101406_bib298","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2337\/dc11-1909","article-title":"Global prevalence and major risk factors of diabetic retinopathy","volume":"35","author":"Yau","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.preteyeres.2025.101406_bib299","first-page":"1524","article-title":"Dexamethasone intravitreal implant for diabetic macular edema in a pregnant patient","volume":"9","author":"Yoo","year":"2016","journal-title":"Int. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0008158","article-title":"Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases","volume":"4","author":"Yoshimura","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.preteyeres.2025.101406_bib301","doi-asserted-by":"crossref","DOI":"10.1016\/j.apjo.2024.100068","article-title":"Genetic association of TIE2 with diabetic retinopathy and diabetic macular edema","volume":"13","author":"Yu","year":"2024","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"10.1016\/j.preteyeres.2025.101406_bib302","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/6329819","article-title":"Diabetic macular oedema guidelines: an Australian perspective","volume":"2023","author":"Yuen","year":"2023","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.preteyeres.2025.101406_bib303","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1001\/jamaophthalmol.2023.2098","article-title":"Systemic adverse events among patients with diabetes treated with intravitreal anti-vascular endothelial growth factor injections","volume":"141","author":"Zafar","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.preteyeres.2025.101406_bib304","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/jama.2010.1111","article-title":"Prevalence of diabetic retinopathy in the United States, 2005-2008","volume":"304","author":"Zhang","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.preteyeres.2025.101406_bib305","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12886-024-03476-9","article-title":"Double-dose investigation of aflibercept in neovascular age-related macular degeneration (DIANA): a real-world study","volume":"24","author":"Zhang","year":"2024","journal-title":"BMC Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101406_bib306","doi-asserted-by":"crossref","DOI":"10.1016\/j.apjo.2024.100067","article-title":"Risk factors for diabetic retinopathy, diabetic macular edema, and sight-threatening diabetic retinopathy","volume":"13","author":"Zhang","year":"2024","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"10.1016\/j.preteyeres.2025.101406_bib307","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1007\/s40123-022-00576-x","article-title":"OCT-Based biomarkers are associated with systemic inflammation in patients with treatment-na\u00efve diabetic macular edema","volume":"11","author":"Zhou","year":"2022","journal-title":"Ophthalmol Ther"}],"container-title":["Progress in Retinal and Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1350946225000795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1350946225000795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T12:19:39Z","timestamp":1766146779000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1350946225000795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":306,"alternative-id":["S1350946225000795"],"URL":"https:\/\/doi.org\/10.1016\/j.preteyeres.2025.101406","relation":{},"ISSN":["1350-9462"],"issn-type":[{"value":"1350-9462","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"International consensuses and controversies on causes, diagnosis and management of diabetic macular edema (DME)","name":"articletitle","label":"Article Title"},{"value":"Progress in Retinal and Eye Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.preteyeres.2025.101406","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101406"}}